Nov. 12 at 1:04 PM
$SPRO What's the goose that lays the golden egg worth to GSK? Tebi sale projections over the next decade may provide a clue. I believe sales could easily tally
$50 billion, if not more, so a
$1-2 billion outlay to buy out Spero feels right.
$20/share would serve as a base case yet the greedy faceless owner(s) of all those dark pool purchases on 5/28 and 10/21 will demand much more. My interests are fully aligned with those greedy bastards so I will root them to shoot for the fence and get
$50 a share! I want
$50 in cash for each of my shares without ever executing a sell order because I trust that GSK will do that for me! Let's all profit from the largesse of the global biopharma gorilla that is GSK. Godspeed to those with conviction!!!
